Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. SEC filings document the company's commercial rare-disease business, including ORLADEYO® results, revenue guidance, pricing disclosures, and financial results furnished on Form 8-K. The filings also describe pipeline and business-development matters involving HAE programs, including navenibart licensing and the completed acquisition of Astria Therapeutics as a BioCryst subsidiary.
BioCryst's filings further cover financing and capital-structure matters, including term-loan arrangements, as well as proxy disclosures on board elections, executive compensation, equity awards, committee structure, and shareholder voting matters. Material-event reports and proxy statements provide the formal record for governance changes, strategic transactions, and Regulation FD disclosures.
BioCryst Pharmaceuticals Chief Legal Officer Alane P. Barnes exercised stock options and sold shares in a planned transaction. On March 16, 2026, she exercised options for 150,000 shares of common stock at an exercise price of $5.51 per share.
The same day, she sold 150,000 shares of common stock at a weighted average price of $9.15 per share, with individual sale prices ranging from $8.95 to $9.57. After these transactions, she directly owned 400,703 shares of common stock. The filing states the sale was made automatically under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025, indicating it was not a discretionary trade.
150,000 shares of Common Stock are listed for sale under Rule 144 in a Form 144 notice dated 03/16/2026. The filing shows an option grant date of 02/27/2017 and cash as the consideration method.
The document names Fidelity Brokerage Services LLC as broker and records a prior sale by Alane Barnes of 21,773 shares on 12/22/2025 for $166,563.45. The filing is a routine resale notice and does not state proceeds recipient beyond the broker listing.
BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received additional company stock as part of her board compensation. On February 27, 2026, she acquired 528 shares of Common Stock at a price of $8.75 per share through a grant classified as a board retainer in stock rather than cash. After this award, she directly owns 15,382 Common Stock shares. A footnote explains the shares were issued in lieu of 100% of her prorated quarterly cash board member retainer of $4,625, meaning the company paid this portion of her board fees in stock instead of cash.
BIOCRYST PHARMACEUTICALS INC director Jon P. Stonehouse reported several equity transactions. On March 2, 2026, he exercised an employee stock option for 305,995 shares of common stock at an exercise price of $3.22 per share, converting the derivative into common stock.
That same day, he reported a disposition of 305,995 common shares at a weighted average price of $8.64 per share; a footnote states these shares were sold in multiple transactions between $8.54 and $8.81 under a pre-established Rule 10b5-1 trading plan, and the transaction occurred automatically. After this, his direct common stock holdings were 1,323,850 shares.
On February 27, 2026, he also acquired 421 common shares at $8.75 per share, issued in lieu of 50% of a prorated quarterly cash board retainer of $7,375. In addition, there are 40,000 common shares held indirectly in each of two irrevocable trusts, where his wife serves as co-trustee.
MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Vincent Milano received 848 shares of Common Stock as a compensation award. The shares were issued at a reference price of $8.75 per share, bringing his directly held total to 92,067 shares after the transaction.
The footnote explains that these shares were issued in lieu of 50% of his quarterly cash Board member retainer of $11,250 and, effective January 23, 2026, in lieu of 50% of the quarterly cash Board Chair retainer of $20,000. This represents routine equity-based director compensation rather than an open-market purchase or sale.
Frank Steven reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Steven Frank received an equity grant of 1,285 shares of Common Stock on February 27, 2026. The shares were issued in lieu of 100% of his quarterly cash board member retainer of $11,250, reflecting a stock-based compensation choice rather than a market purchase. Following this award, he directly owns 18,903 shares of the company’s common stock.
McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Amy E. McKee reported receiving an award of 642 shares of common stock on February 27, 2026. The shares were issued in lieu of 50% of a quarterly cash board retainer of $11,250, bringing her direct holdings to 42,432 shares.
BioCryst Pharmaceuticals outlines a rare-disease focused strategy centered on hereditary angioedema (HAE) and other orphan conditions. The company’s core product, ORLADEYO, is an oral, once-daily prophylactic for HAE, now approved in multiple markets and expanded to children aged 2 to <12 years via a pellet formulation in the United States.
BioCryst is leveraging this commercial platform with a pipeline that includes navenibart, a Phase 3 anti‑kallikrein antibody for HAE acquired through the Astria Therapeutics merger, BCX17725 for Netherton syndrome, and avoralstat for diabetic macular edema. The report details extensive global partnerships for ORLADEYO, legacy influenza antiviral peramivir (RAPIVAB) supply to the U.S. Strategic National Stockpile, and a broad patent estate protecting kallikrein, antiviral, and other programs, while emphasizing numerous clinical, regulatory, competitive, financing, and operational risks that could impact profitability and growth.